Study of eribulin plus trastuzumab in pretreated HER2-positive advanced breast cancer (ABC) patients
Latest Information Update: 27 Dec 2019
At a glance
- Drugs Eribulin (Primary) ; Trastuzumab (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions; Therapeutic Use
- 11 Oct 2016 Results assessing safety efficacy presented at the 41st European Society for Medical Oncology Congress.
- 27 Jul 2016 New trial record
- 07 Jun 2016 Results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology